Customized phage therapies to eradicate
harmful bacteria in chronic diseases
– Expect to initiate Phase 1a clinical study of BX002 for the treatment of IBD in the third quarter of 2020; pharmacokinetics results expected by the end of 2020
– On track for Phase 2 cosmetic clinical study of BX001 in acne first quarter of 2021
– Cash and equivalents of $70.6 million expected to fund current operating plan through mid-2022
– Company to host conference call today at 8:00 a.m. Eastern Time
Ness Ziona, Israel – Aug. 6, 2020 – BiomX Inc. (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and live...
Positive Phase 1 cosmetic clinical study results of BX001 in acne-prone skin reported; planned advance to Phase 2 study with readout expected in the second quarter of 2021. Initial BX002 Phase 1 clinical study readout in inflammatory bowel disease expected in the fourth quarter of 2020